Blueprint Medicines (BPMC) Tops Q3 EPS by 18c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.20), $0.18 better than the analyst estimate of ($2.38). Revenue for the quarter came in at $56.56 million versus the consensus estimate of $50.66 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
• Waste stocks ride AI and healthcare boom as CLH surges 27%